P. Jones

发表

Effects of conjugated linoleic acid (CLA) isomers on lipid levels and peroxisome proliferation in the hamster

J. M. V. van Amelsvoort, E. A. de Deckere, G. Mcneill, 1999, British Journal of Nutrition.

A clinical overview of dyslipidemias: treatment strategies.

P. Jones, Peter H. Jones, 1992, The American journal of medicine.

The diagnosis and management of hyperlipidemia.

A. Gotto, P. Jones, L. Scott, 1986, Disease-a-month : DM.

Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA).

D. Azagury, N. Nguyen, S. Kothari, 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations.

A. Gotto, J. Farmer, C. Ballantyne, 1992, Journal of the American College of Cardiology.

Lovastatin and simvastatin prevention studies.

P. Jones, 1990, The American journal of cardiology.

Treatment of dyslipidemias.

P. Jones, 1996, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Extending the benefit of lipid-regulating therapy to primary prevention.

A. Gotto, P. Jones, 1995, The American journal of cardiology.

Prevention of coronary heart disease in 1994: evidence for intervention.

A. Gotto, P. Jones, 1994, Heart disease and stroke : a journal for primary care physicians.

Effects of lipid lowering therapy on progression of coronary and carotid artery disease.

A. Gotto, J. Farmer, C. Ballantyne, 1997, Current Opinion in Lipidology.

Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group.

A. Gotto, S. Kelsey, D. Illingworth, 1992, The American journal of cardiology.

Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin).

A. Gotto, G. Noon, C. Ballantyne, 1987, Transplantation proceedings.

Two-year follow-up of patients treated with a very-low-calorie diet and exercise training.

A. Gotto, J. Foreyt, P. Jones, 1988, Journal of the American Dietetic Association.

Modest Diet-Induced Weight-Loss Reduces Macrophage Cholesterol Efflux to Plasma of Metabolic Syndrome Patients

C. Ballantyne, H. Pownall, P. Jones, 2014 .

Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.

A. Gotto, J. Farmer, H. Pownall, 1996, Journal of lipid research.

Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.

S. Schwartz, H. Haber, S. Weiss, 1997, The American journal of cardiology.

patient-oriented and epidemiological research Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

E. Schaefer, E. Stein, M. Ai, 2009 .

Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.

A. Gotto, J. Farmer, D. Shapiro, 1992, Clinical therapeutics.

Fibrates and high-dose statins to prevent coronary heart disease events

P. Jones, 1999, Current cardiology reports.

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.

A. Gotto, J. Farmer, C. Ballantyne, 1999, Circulation.

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

D. Hunninghake, P. Jones, S. Kafonek, 1998, The American journal of cardiology.

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).

A. Gotto, J. Farmer, C. Ballantyne, 1997, The American journal of cardiology.

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

J. Isaacsohn, B. Gordon, S. Weiss, 1999, Archives of internal medicine.

Indications for low-density lipoprotein apheresis.

D. Illingworth, E. Stein, B. Gordon, 1994, The American journal of cardiology.

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

D. Sprecher, S. Schwartz, H. Haber, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Future of lipid-lowering trials: what else do we need to know?

P. Jones, 1998, The American journal of cardiology.

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

J. D. Proctor, J. Mckenney, J. Farmer, 1991, Clinical cardiology.

Impact of weight loss on the metabolic syndrome

C. Ballantyne, E. Smith, C. Case, 2002, Diabetes, obesity & metabolism.

Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.

D. Hunninghake, W. Insull, M. Davidson, 2001, The American journal of cardiology.

The nature of the statins.

P. Jones, 2000, Circulation.

P2362 Statin therapies for elevated lipid levels compared across doses to rosuvastatin (STELLAR): non-high-density lipoprotein cholesterol results and goals

P. Jones, 2003 .

Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group.

A. Gotto, S. Kelsey, D. Illingworth, 1998, The American journal of cardiology.